Role of targeted therapy in metastatic colorectal cancer

doi:10.4251/wjgo.v8.i9.642

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11783)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

1020

WORD

344

HTML

7466

Tables (1-4)

292

Sum=9122

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1071

Download

1590

Sum=2661

Sep 15, 2016 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (75)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Sep 15, 2016; 8(9): 642-655
Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.642

Table 1 Clinical trials of anti-angiogenic therapies in metastatic colorectal cancer

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
First-line chemotherapy
AVF2017g	IFL + Bevacizumab	402	44.8%	10.6	20.3
BICC-C	FOLFIRI + Bevacizumab	57	57.9%	11.2	28.0
NO16966	FOLFOX/CapeOX + Bevacizumab	699	38%	9.4	21.3
TREE-1/2	FOLFOX + Bevacizumab	71	52%	9.9	26.1
CAIRO2	CapeOX + Bevacizumab	378	50%	10.7	20.3
SOFT	SOX + Bevacizumab	256	61.5%	11.7	29.6
TRIBE	FOLFOXIRI + Bevacizumab	252	65.1%	12.1	31.0
AVEX¹	Capecitabine + Bevacizumab	140	19.3%	9.1	20.7
Second-line, salvage-line chemotherapy, or beyond progression
E3200	FOLFOX + Bevacizumab	286	22.7%	7.3	12.9
ML18147	Chemotherapy + Bevacizumab	410	5.4%	5.7	11.2
C-TASK FORCE	TAS-102 + Bevacizumab	25	4.0%	5.6	11.2
VELOUR	FOLFIRI + Aflibercept	612	19.8%	6.9	13.5
RAISE	FOLFIRI + Ramucirumab	536	13.4%	5.7	13.3
CORRECT	Regorafenib	505	1.0%	1.9	6.4

¹AVEX trial enrolled mCRC patients aged 70 years and older. ORR: Objective response rate; PFS: Progression-free survival; IFL: Bolus 5-fluorouracil/leucovorin/irinotecan; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin; CapeOX: Capecitabine/oxaliplatin; SOX: S-1 (tegafur/gimeracil/oteracil)/oxaliplatin; FOLFOXIRI: Infusional 5-fluorouracil/leucovorin/irinotecan/oxaliplatin; OS: Overall survival; mCRC: Metastatic colorectal cancer.

Table 2 Clinical trials of anti-epidermal growth factor receptor therapies in metastatic colorectal cancer with KRAS wild type

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
First-line chemotherapy
CRYSTAL	FOLFIRI + Cetuximab	316	57.3%	9.9	23.5
OPUS	FOLFOX + Cetuximab	159	57%	8.3	22.8
COIN	FOLFOX/CapeOX + Cetuximab	362	64%	8.6	17.0
NORDIC-VII	FLOX + Cetuximab	97	46%	7.9	20.1
PRIME	FOLFOX + Panitumumab	325	55%	9.6	23.9
Second-line, salvage-line chemotherapy, or beyond progression
20050181 trial	FOLFIRI + Panitumumab	303	36%	6.7	14.5
PICCOLO	Irinotecan + Panitumumab	230	34%	5.5	10.4
CO.17	Cetuximab	117	13%	3.7	9.5
20020408 trial	Panitumumab	124	17%	12.3 wk	8.1

ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin; CapeOX: Capecitabine/oxaliplatin; FLOX: Bolus 5-fluorouracil/leucovorin/oxaliplatin.

Table 3 Clinical trials comparing anti-epidermal growth factor receptor therapy vs anti-vascular endothelial growth factor therapy in metastatic colorectal cancer with KRAS wild type

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
First-line chemotherapy
PEAK	FOLFOX + Panitumumab	142	57.8%	10.9	34.2
	FOLFOX + Bevacizumab	143	53.5%	10.1	24.3
	(HR, P-value)		-	HR = 0.87	HR = 0.62
	(HR, P-value)		-	P = 0.353	P = 0.009
FIRE-3	FOLFIRI + Cetuximab	297	62%	10.0	28.7
	FOLFIRI + Bevacizumab	295	58%	10.3	25.0
	(HR, P-value)		OR = 1.18	HR = 1.06	HR = 0.77
	(HR, P-value)		P = 0.18	P = 0.55	P = 0.017
CALGB/SWOG 80405	Chemotherapy¹ + Cetuximab	578	65.6%	10.4	29.9
	Chemotherapy¹ + Bevacizumab	559	57.2%	10.8	29.0
	(HR, P-value)		P = 0.02	HR = 1.04	HR = 0.925
	(HR, P-value)		P = 0.02	P = 0.55	P = 0.34
Second-line chemotherapy
SPIRITT	FOLFIRI + Panitumumab	91	32%	7.7	18.0
	FOLFIRI + Bevacizumab	91	19%	9.2	21.4
	(HR, P-value)		-	HR = 1.01	HR = 1.06
	(HR, P-value)		-	P = 0.97	P = 0.75

¹Chemotherapy regimens were FOLFOX or FOLFIRI. ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; HR: Hazard ratio; OR: Odds ratio; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin.

Table 4 Treatment outcome by anti-epidermal growth factor receptor therapy as first-line treatment in metastatic colorectal cancer with RAS wild type

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
CRYSTAL	FOLFIRI + Cetuximab	178	66.3%	11.4	28.4
	FOLFIRI	189	38.6%	8.4	20.2
	(HR, P-value)		OR = 3.31	HR = 0.56	HR = 0.69
	(HR, P-value)		P < 0.001	P = 0.0002	P = 0.0024
PRIME	FOLFOX + Panitumumab	259	-	10.1	25.8
	FOLFOX	253	-	7.9	20.2
	(HR, P-value)		-	HR = 0.72	HR = 0.77
	(HR, P-value)		-	P = 0.004	P = 0.009
PEAK	FOLFOX + Panitumumab	88	63.6%	13.0	41.3
	FOLFOX + Bevacizumab	82	60.5%	9.5	28.9
	(HR, P-value)		-	HR = 0.65	HR = 0.63
	(HR, P-value)		-	P = 0.029	P = 0.058
FIRE-3	FOLFIRI + Cetuximab	171	65%	10.4	33.1
	FOLFIRI + Bevacizumab	171	60%	10.2	25.6
	(HR, P-value)		OR = 1.28	HR = 0.93	HR = 0.70
	(HR, P-value)		P = 0.32	P = 0.54	P = 0.011
CALGB/SWOG 80405	Chemotherapy¹ + Cetuximab	270	68.6%	11.4	32.0
	Chemotherapy¹ + Bevacizumab	256	53.8%	11.3	31.2
	(HR, P-value)		P < 0.01	HR = 1.1	HR = 0.9
	(HR, P-value)		P < 0.01	P = 0.31	P = 0.4

Citation: Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655
URL: https://www.wjgnet.com/1948-5204/full/v8/i9/642.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i9.642